ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis, demonstrating that 88% of participants prefer ...

ALK’s new data reveals 9 in 10 people prefer EURneffy, a needle-free nasal adrenaline spray, over auto-injectors: Denmark Monday, March 2, 2026, 18:00 Hrs [IST] ALK, a global sp ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

Royal College of Art graduates are using their creative training to build companies – from life-saving medical devices to award-winning design studios – thanks to mentorship, seed funding and a cultur ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Great. Good morning, everybody. I'm Luke Sergott, I cover Life Science Tools Diagnostics here for Barclays. With me, I have Eric Green, CEO; and Bob McMahon, CFO; and we have John Sweeney over there ...

EXCLUSIVE: It's understood Labour MPs are being whipped to vote against an amendment which could 'save children's lives'.

Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even Conference call to be held today, March 9, ...

・It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats.

Bill Gates is one of the most well-known billionaires in the world. The Microsoft founder became the wealthiest person in the world in the late 1990s, as the tech company's value soared. Despite ...

In a significant leap forward for obesity care, Eli Lilly has officially launched a new formulation of its blockbuster drug, Zepbound, consolidating an entire month of treatment into a single, ...